Category: Pharma, Life Sciences & Med Tech Players
-
District judge opens door to rare “reverse doctrine of equivalents” defense in medical device dispute
The judge’s order came amid long-running litigation between Maquet and Abiomed in the United States District Court for the District of Massachusetts over intravascular blood pump technologies.
-
Federal Circuit analysis would create “substantial disincentive” to generic entry, USDOJ tells Supreme Court in Hikma v. Amarin
The key arguments centred on whether it was plausible that Hikma’s marketing amounted to inducement to infringe.
-
Merz wins UPC appeal as CoA overturns Paris LD denial and grants PI against Viatris generic in France
The UPC CoA has reversed the Paris LD’s refusal of interim relief and granted Merz a preliminary injunction against Viatris Santé’s fampridine generic in France.
-
Pfizer settles with three Vyndamax generic challengers mid-trial, extends exclusivity, presumably through pay-for-delay
Pfizer has quickly reached a settlement with Cipla, Hikma, and Dexcel during a five-day bench trial in Delaware, ending the dispute and extending its effective monopoly.
-
CureVac sues Moderna in Delaware over Spikevax patents, seeking treble damages but no injunction
CureVac sues Moderna for treble damages but not an injunction over 10 patents related to Spikevax. The case adds to broader post-COVID mRNA patent battles.
-
Human lives at stake: Munich court warns against chilling effect of excessive prior art eligibility as rivaroxaban dispute heads into final round
All other Munich landmark rulings related to access to injunctive relief, be it about SEPs, the invalidity defense to PIs, or anti-antisuit relief in different forms. The latest one is about patients more so than patents.
-
Federal Circuit revives Teva’s $177M (potentially $530M) damages verdict against Eli Lilly over Emgality headache drug
A $177M jury verdict, potentially tripled for willfulness, has been reinstated, and the standards for written description and enablement for genus-related patents have been clarified.
-
SĂŁo Paulo court grants Johnson & Johnson extraordinary emergency relief and reinstates injunction in med tech patent dispute
The President of the Private Law Section of the SĂŁo Paulo Court of Justice granted extraordinary emergency relief, reinstating an injunction previously lifted on appeal in this med tech patent dispute, in a procedurally unusual intervention.
-
Another semaglutide generic enters India as Novo Nordisk patent expires, no injunction issuesÂ
The Delhi High Court has issued a ruling allowing a generic version of semaglutide to be sold without an injunction and indicating a cautious approach to late-stage enforcement, favoring restricted entry over exclusion, by basing it around a contested claim limitation.
-
Colombia pushes for compulsory licensing of U.S. pharma company’s patents
Colombia’s Health Minister has revived a previous administration’s investigation into four of U.S. pharma company Gilead’s patents at the core of Hepatitis-C treatment, issuing a public interest declaration to make the licensing of such patents compulsory.